Prior to joining Pharmalink, Aguiar-Lucander was Partner and COO of Omega Fund Management, an international healthcare fund based in Boston. She was previously a Partner at the venture group of 3i Group plc, where she managed the European and US legacy healthcare and technology portfolios, and had responsibility for the group’s public holdings. Prior to this, Aguiar-Lucander was European Group Head and Managing Director at a US based global investment bank. Aguiar-Lucander holds a BA in Finance from Stockholm School of Economics and a MBA from INSEAD.

Pharmalink’s current CEO, Dr Johan Häggblad, will take on the role of COO and will continue to lead clinical and product development.